BioNTech SE (BNTX) has released an update.
BioNTech SE and Genmab have revealed promising initial data from a Phase 2 trial of acasunlimab in combination with pembrolizumab, showing significant survival benefits for patients with previously treated metastatic non-small cell lung cancer. The combination therapy demonstrated a 12-month overall survival rate of 69% with a median overall survival of 17.5 months, outperforming monotherapy results. These findings are informing the upcoming Phase 3 trial, aiming to offer a new treatment option for this patient group.
For further insights into BNTX stock, check out TipRanks’ Stock Analysis page.
